Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;3(12):893-6.
doi: 10.4103/2008-7802.104862.

Oral contraceptive therapy increases oxidative stress in pre-menopausal women

Jui Tung Chen  1 , Kazuhiko Kotani
Affiliations

Oral contraceptive therapy increases oxidative stress in pre-menopausal women

Jui Tung Chen et al. Int J Prev Med. 2012 Dec.

Abstract

Background: Oral contraceptive therapy (OCT) is associated with an increased risk of deep vein thrombosis, venous thromboembolism and stroke. However, the underlying mechanisms have not yet been elucidated. The objective of this study was to investigate the influence of OCT on blood levels of an oxidative stress maker in pre-menopausal women.

Methods: Oxidative stress was determined in 87 pre-menopausal healthy women (24 with and 63 without OCT) using a blood assay for reactive oxygen metabolites (by the d-ROMs test). The subjects with OCT received a triphasic preparation consisting of ethinyl estradiol and norethisterone.

Results: Subjects with OCT showed significantly higher d-ROMs levels (median: 380; interquartile range: 328-502 Carr U) than those without OCT (325 [271-369]; P < 0.05). The results remained the same after adjusting for potential confounders.

Conclusions: The use of OCT may increase oxidative stress levels, independent of traditional cardiovascular risk factors, in pre-menopausal women, providing new insights to the primary prevention of vascular complications in these subjects.

Keywords: Contraceptives; d-ROMs test; ethinyl estradiol; norethisterone; oxidative stress marker.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Spencer AL, Bonnema R, McNamara MC. Helping women choose appropriate hormonal contraception: Update on risks, benefits, and indications. Am J Med. 2009;122:497–506. - PubMed
    1. Collins P, Rosano GMC, Sarrell PM. 17b-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 1995;92:24–30. - PubMed
    1. World health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet. 1995;346:1575–82. - PubMed
    1. Kemmeren JM, Tanis BC, van der Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202–8. - PubMed
    1. Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric. 2008;11:355–63. - PubMed

LinkOut - more resources